Silver Book Fact

Vaccines in development 2013

Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.

Pharmaceutical Researchers and Manufacturers of America. Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines. Washington, D.C.: PhRMA; 2013. http://phrma.org/medicines-in-development-for-vaccines-2013

Reference

Title
Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines
Publisher
PhRMA
Publication Date
2013
Authors
Pharmaceutical Researchers and Manufacturers of America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Over 6 years, flu vaccine prevented ~13 million cases
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.  
  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Shingles vaccine reduces incidence by >50%
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.